Home › Pheochromocytoma
Pheochromocytoma clinical trials recruiting in the U.S.
16 studies for Pheochromocytoma are recruiting participants at sites across the United States.
Pheochromocytoma is a rare tumor. Pheochromocytomas often cause the adrenal gland to make too many hormones. This can lead to high blood pressure.
Cities with the most studies
- Washington, DC9 studies
- Nashville, TN3 studies
- Cedar Rapids, IA3 studies
- Chicago, IL3 studies
- Baltimore, MD3 studies
- Philadelphia, PA3 studies
- Los Angeles, CA3 studies
By state
- California3 studies
- Illinois3 studies
- Iowa3 studies
- Maryland10 studies
- Michigan3 studies
- Pennsylvania3 studies
- Tennessee4 studies
- Texas3 studies
Recently updated studies
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 29, 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 25, 2026 · NCT04924075Diagnosis of Pheochromocytoma
RecruitingPhase 1
Ages 3 to 120 · All sexes · Updated Sep 22, 2026 · NCT00004847Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Aug 25, 2026 · NCT03206060Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Aug 24, 2026 · NCT00001238Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 18, 2026 · NCT06427798Using the EHR to Advance Genomic Medicine Across a Diverse Health System
Recruiting
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT06377033Familial Investigations of Childhood Cancer Predisposition
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Jun 15, 2026 · NCT06041516Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RecruitingPhase 2
Ages 1 and older · All sexes · Updated May 29, 2026 · NCT0010728918F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated May 19, 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
Ages 18 to 90 · All sexes · Updated May 14, 2026 · NCT05636618Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Mar 17, 2026 · NCT04119024In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Feb 27, 2026 · NCT05636540Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Oct 15, 2025 · NCT03160274From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.